Janular 50/500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of incretin hormones, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The synergistic action of these agents helps achieve optimal glycemic control in patients inadequately controlled on diet and exercise alone or as an adjunct to other antidiabetic therapies. Janular 50/500 is typically administered orally, with dosage individualized based on patient response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily related to metformin. Rare but serious side effects include lactic acidosis and pancreatitis. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiac conditions. Regular monitoring of blood glucose levels, renal function, and other relevant parameters is recommended to ensure safety and efficacy. Janular 50/500 Tablet should be used under medical supervision as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.